{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:56:16Z","timestamp":1785452176067,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T00:00:00Z","timestamp":1471910400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s12016-016-8581-4","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T02:23:39Z","timestamp":1471919019000},"page":"389-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis"],"prefix":"10.1007","volume":"52","author":[{"given":"Li-Jun","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Lian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Yan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Chun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,23]]},"reference":[{"key":"8581_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0022-3476(05)80742-5","volume":"119","author":"KA Taubert","year":"1991","unstructured":"Taubert KA, Rowley AH, Shulman ST (1991) Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 119:279\u2013282","journal-title":"J Pediatr"},{"key":"8581_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJM198608073150601","volume":"315","author":"JW Newburger","year":"1986","unstructured":"Newburger JW, Takahashi M, Burns JC et al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341\u2013347","journal-title":"N Engl J Med"},{"key":"8581_CR3","first-page":"CD004000","volume":"4","author":"RM Oates-Whitehead","year":"2003","unstructured":"Oates-Whitehead RM, Baumer JH, Haines L et al (2003) Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 4:CD004000","journal-title":"Cochrane Database Syst Rev"},{"key":"8581_CR4","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.jacc.2015.12.073","volume":"67","author":"JW Newburger","year":"2016","unstructured":"Newburger JW, Takahashi M, Burns JC (2016) Kawasaki disease. J Am Coll Cardiol 67:1738\u20131749","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"8581_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jinf.2016.04.015","volume":"72","author":"AJ Campbell","year":"2016","unstructured":"Campbell AJ, Burns JC (2016) Adjunctive therapies for Kawasaki disease. J Infect 72(Suppl):S1\u2013S5","journal-title":"J Infect"},{"key":"8581_CR6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jpeds.2010.06.014","volume":"157","author":"NF Choueiter","year":"2010","unstructured":"Choueiter NF, Olson AK, Shen DD et al (2010) Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr 157:960\u2013966","journal-title":"J Pediatr"},{"key":"8581_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jpeds.2010.10.012","volume":"158","author":"MB Son","year":"2011","unstructured":"Son MB, Gauvreau K, Burns JC et al (2011) Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 158:644\u2013649","journal-title":"J Pediatr"},{"key":"8581_CR8","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(13)62298-9","volume":"383","author":"AH Tremoulet","year":"2014","unstructured":"Tremoulet AH, Jain S, Jaggi P et al (2014) Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 383:1731\u20131738","journal-title":"Lancet"},{"key":"8581_CR9","unstructured":"Wells GSB, O\u2019Connel D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis Ottawa Hospital Research Institute Web site http:\/\/www.ohri.ca\/programs\/clinicalepidemiology\/oxford.asp"},{"key":"8581_CR10","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, PRISMA Group et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006\u20131012","journal-title":"J Clin Epidemiol"},{"key":"8581_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"8581_CR12","doi-asserted-by":"publisher","unstructured":"Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG (eds) Systematic reviews in health care: meta-analysis in context, 2nd edn. BMJ Publishing Group, London, pp 285\u2013312","DOI":"10.1002\/9780470693926.ch15"},{"key":"8581_CR13","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088\u20131101","journal-title":"Biometrics"},{"key":"8581_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"8581_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","volume":"153","author":"JC Burns","year":"2008","unstructured":"Burns JC, Best BM, Mejias A et al (2008) Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 153:833\u2013838","journal-title":"J Pediatr"},{"key":"8581_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/cei.12182","volume":"174","author":"JC Burns","year":"2013","unstructured":"Burns JC, Song Y, Bujold M et al (2013) Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clin Exp Immunol 174:337\u2013344","journal-title":"Clin Exp Immunol"},{"key":"8581_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/INF.0000000000001039","volume":"35","author":"Y Youn","year":"2016","unstructured":"Youn Y, Kim J, Hong YM et al (2016) Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatr Infect Dis J 35:457\u2013459","journal-title":"Pediatr Infect Dis J"},{"key":"8581_CR18","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1136\/archdischild-2014-307536","volume":"100","author":"S Singh","year":"2015","unstructured":"Singh S, Vignesh P, Burgner D (2015) The epidemiology of Kawasaki disease: a global update. Arch Dis Child 100:1084\u20131088","journal-title":"Arch Dis Child"},{"key":"8581_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrrheum.2015.54","volume":"11","author":"ST Shulman","year":"2015","unstructured":"Shulman ST, Rowley AH (2015) Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol 11:475\u2013482","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"8581_CR20","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s00246-015-1138-0","volume":"36","author":"M Wei","year":"2015","unstructured":"Wei M, Huang M, Chen S et al (2015) A multicenter study of intravenous immunoglobulin non-response in Kawasaki disease. Pediatr Cardiol 36(6):1166\u20131172","journal-title":"Pediatr Cardiol"},{"key":"8581_CR21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/INF.0b013e31815922b5","volume":"27","author":"R Uehara","year":"2008","unstructured":"Uehara R, Belay ED, Maddox RA et al (2008) Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 27:155\u2013160","journal-title":"Pediatr Infect Dis J"},{"key":"8581_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/heartjnl-2012-302126","volume":"99","author":"S Chen","year":"2013","unstructured":"Chen S, Dong Y, Yin Y et al (2013) Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 99:76\u201382","journal-title":"Heart"},{"key":"8581_CR23","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1542\/peds.2004-2182","volume":"114","author":"JW Newburger","year":"2004","unstructured":"Newburger JW, Takahashi M, Gerber MA, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association et al (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114:1708\u20131733","journal-title":"Pediatrics"},{"key":"8581_CR24","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0022-3476(97)70038-6","volume":"131","author":"M Terai","year":"1997","unstructured":"Terai M, Shulman ST (1997) Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 131:888\u2013893","journal-title":"J Pediatr"},{"key":"8581_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0022-3476(05)80972-2","volume":"123","author":"RP Sundel","year":"1993","unstructured":"Sundel RP, Burns JC, Baker A (1993) Gamma globulin re-treatment in Kawasaki disease. J Pediatr 123:657\u2013659","journal-title":"J Pediatr"},{"key":"8581_CR26","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1097\/00006454-199812000-00009","volume":"17","author":"JC Burns","year":"1998","unstructured":"Burns JC, Capparelli EV, Brown JA (1998) Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US\/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 17:1144\u20131148","journal-title":"Pediatr Infect Dis J"},{"key":"8581_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1442-200x.2001.01373.x","volume":"43","author":"K Hashino","year":"2001","unstructured":"Hashino K, Ishii M, Iemura M et al (2001) Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 43:211\u2013217","journal-title":"Pediatr Int"},{"key":"8581_CR28","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/adc.2004.062299","volume":"90","author":"M Miura","year":"2005","unstructured":"Miura M, Ohki H, Yoshiba S et al (2005) Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 90:1096\u20131097","journal-title":"Arch Dis Child"},{"key":"8581_CR29","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1542\/peds.2011-0148","volume":"129","author":"S Ogata","year":"2012","unstructured":"Ogata S, Ogihara Y, Honda T et al (2012) Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 129:e17\u2013e23","journal-title":"Pediatrics"},{"key":"8581_CR30","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(11)61930-2","volume":"379","author":"T Kobayashi","year":"2012","unstructured":"Kobayashi T, Saji T, Otani T, RAISE study group investigators et al (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379:1613\u20131620","journal-title":"Lancet"},{"key":"8581_CR31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00431-011-1585-4","volume":"171","author":"BH Zhu","year":"2012","unstructured":"Zhu BH, Lv HT, Sun L et al (2012) A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr 171:571\u2013578","journal-title":"Eur J Pediatr"},{"key":"8581_CR32","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1017\/S1047951114002601","volume":"25","author":"X Yang","year":"2015","unstructured":"Yang X, Liu G, Huang Y et al (2015) A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease. Cardiol Young 25:1182\u20131190","journal-title":"Cardiol Young"},{"key":"8581_CR33","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/jcpt.12334","volume":"40","author":"RM Patel","year":"2015","unstructured":"Patel RM, Shulman ST (2015) Kawasaki disease: a comprehensive review of treatment options. J Clin Pharm Ther 40:620\u2013625","journal-title":"J Clin Pharm Ther"},{"key":"8581_CR34","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jpeds.2010.10.031","volume":"158","author":"LA Sleeper","year":"2011","unstructured":"Sleeper LA, Minich LL, McCrindle BM, Pediatric Heart Network Investigators et al (2011) Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 158:831\u2013835.e3","journal-title":"J Pediatr"},{"key":"8581_CR35","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrcardio.2009.57","volume":"6","author":"GE McKellar","year":"2009","unstructured":"McKellar GE, McCarey DW, Sattar N et al (2009) Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 6:410\u2013417","journal-title":"Nat Rev Cardiol"},{"key":"8581_CR36","doi-asserted-by":"publisher","unstructured":"Yang ZS, Lin NN, Li L, et al (2016) The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis. Clin Rev Allergy Immunol (in press)","DOI":"10.1007\/s12016-016-8560-9"},{"key":"8581_CR37","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1161\/CIRCULATIONAHA.114.012900","volume":"131","author":"M Behnes","year":"2015","unstructured":"Behnes M, Akin I, Borggrefe M et al (2015) Effect of tumor necrosis factor inhibitor treatment on proximal right coronary chronic total occlusion in a patient with rheumatoid arthritis. Circulation 131:e26\u2013e28","journal-title":"Circulation"},{"issue":"1","key":"8581_CR38","first-page":"68","volume":"34","author":"I Olivieri","year":"2016","unstructured":"Olivieri I, Cortesi PA, de Portu S, PACE Working Group et al (2016) Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. Clin Exp Rheumatol 34(1):68\u201375","journal-title":"Clin Exp Rheumatol"},{"key":"8581_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1442-200X.2011.03487.x","volume":"54","author":"T Hokosaki","year":"2012","unstructured":"Hokosaki T, Mori M, Nishizawa T et al (2012) Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr Int 54:99\u2013103","journal-title":"Pediatr Int"},{"key":"8581_CR40","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3349\/ymj.2008.49.5.714","volume":"49","author":"TJ Lee","year":"2008","unstructured":"Lee TJ, Kim KH, Chun JK et al (2008) Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J 49:714\u2013718","journal-title":"Yonsei Med J"},{"key":"8581_CR41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jpeds.2012.02.048","volume":"161","author":"AH Tremoulet","year":"2012","unstructured":"Tremoulet AH, Pancoast P, Franco A et al (2012) Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 161:506\u2013512.e1","journal-title":"J Pediatr"},{"key":"8581_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1546-0096-12-26","volume":"12","author":"A Shafferman","year":"2014","unstructured":"Shafferman A, Birmingham JD, Cron RQ (2014) High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J 12:26","journal-title":"Pediatr Rheumatol Online J"},{"key":"8581_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cct.2016.04.002","volume":"48","author":"AH Tremoulet","year":"2016","unstructured":"Tremoulet AH, Jain S, Kim S et al (2016) Rationale and study design for a phase I\/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). Contemp Clin Trials 48:70\u201375","journal-title":"Contemp Clin Trials"},{"key":"8581_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00246-013-0746-9","volume":"35","author":"E Niedra","year":"2014","unstructured":"Niedra E, Chahal N, Manlhiot C et al (2014) Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms. Pediatr Cardiol 35:89\u201392","journal-title":"Pediatr Cardiol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-016-8581-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8581-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8581-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8581-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T21:46:52Z","timestamp":1657144012000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-016-8581-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,23]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["8581"],"URL":"https:\/\/doi.org\/10.1007\/s12016-016-8581-4","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,23]]}}}